Q-omics provides the consensus-scored ZMPSTE24 profile across patient tissues and cancer cell-line models. ZMPSTE24 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, ZMPSTE24 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, ZMPSTE24 protein abundance shows 21,985 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight CESC, KICH, and UCEC as cancer lineages where ZMPSTE24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZMPSTE24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZMPSTE24 survival associations across molecular data types. ZMPSTE24 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZMPSTE24 RNA expression–survival associations across cancer types. High ZMPSTE24 expression shows unfavorable associations in CESC, KIRP, LGG, LIHC and UVM, but favorable associations in KIRC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify CESC as the clearest survival context for ZMPSTE24 RNA expression.
This table summarizes ZMPSTE24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZMPSTE24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZMPSTE24 shows lower tumor expression in KICH, THCA and KIRC and higher tumor expression in HNSC, LIHC and BRCA. The KICH box plot shows higher ZMPSTE24 RNA expression in normal versus tumor tissue (log2 FC = −1.471, t-test p < 0.001).
This table shows molecular features associated with ZMPSTE24 in patient tissues and cancer cell lines. In patient samples, ZMPSTE24 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZMPSTE24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
